×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

cureTV – Empowering Patients Through Video

Jarushka Naidoo, MBBCh
Immunotherapy use continues to expand in the cancer treatment space. So, it is important that patients and caregivers understand its potential side effects.
Sagar Lonial, M.D.
The definition of smoldering myeloma was reworked in recent years. 
John Marshall, M.D.
Colorectal cancer expert John Marshall, M.D., shares his feelings about the month of March, which is Colorectal Cancer Awareness month.
Ruben Mesa, M.D.
Ruben Mesa, M.D., director of the UT Health San Antonio Cancer Center, discusses complementary therapy for patients with myeloproliferative neoplasms (MPNs).
Joshua Bauml, M.D.
Joshua Bauml, M.D., assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the potential of therapeutic vaccine in patients who have head and neck cancer.
William G. Wierda, M.D., Ph.D.
William G. Wierda, M.D., Ph.D., medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses how to best combine and sequence therapies for patients with chronic lymphocytic leukemia (CLL).
Joshua Richter, M.D.
A new patient-reported outcomes tool is helping to shift the way end-of-life and depression-related conversations are occurring between patients with multiple myeloma and their health care teams.
Michael J. Overman, M.D.
Genetic testing – particularly for microsatellite instability (MSI) – is an important step for all patients diagnosed with colorectal cancer.
Tom Stockwell
Now that we're in an era of personalized medicine, patients should not look at statistics and immediately think that they will determine their fate, says Tom Stockwell, patient navigator at the Fibrolamellar Cancer Foundation.
Radhakrishnan Ramchandren, M.D.
Radhakrishnan Ramchandren, M.D., from the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, discusses the role of clinical trials in developing news drugs and standards of care for patients with lymphoma.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable